ICP-033 / InnoCare - LARVOL DELTA

A Study of ICP-033 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

New P1 trial • Oncology • Solid Tumor

InnoCare puts RTK Inhibitor ICP-033 into Phase I in China (GBI Health) - "China-based biotech InnoCare (HKEX: 09969) announced the receipt of a first clinical trial approval for ICP-033, which will enter a Phase I study in China. The drug, a novel receptor tyrosine kinase (RTK) inhibitor is InnoCare’s sixth product candidate to reach the clinic...ICP-033 will be developed as both a monotherapy and in combination with other immunotherapies against solid tumors including liver cancer, renal cell carcinoma, colorectal cancer, and others."

New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Liver Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China (PRNewswire) - “InnoCare…announced today that China's National Medical Products Administration (NMPA) has approved the initiation of a Phase I clinical trial of ICP-033, the Company's novel RTK (Receptor Tyrosine Kinase) inhibitor and its sixth innovative drug to enter clinical development…‘and it will further enrich our product pipeline in the field of solid tumors and potentially provide another treatment option for cancer patients worldwide.’”

New P1 trial • Oncology • Solid Tumor

InnoCare’s RTKs inhibitor ICP-033 under trial review in China (GBI Health) - China-based biopharma Guangzhou InnoCare Pharma Tech Co., (09969.HK) announced that an investigational new drug filing for its multiple receptor tyrosine kinases (RTKs) inhibitor ICP-033 has been accepted for review by the National Medical Products Administration."

Non-US regulatory • Oncology

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 (PRNewswire) - “ICP-189: It is being developed for the treatment of solid tumors as a single agent and/or in combinations with other anti-tumor agents. We plan to submit the IND application for ICP-189 to the CDE in the second half of 2021; ICP-033: ICP-033 is intended to be used in combination with immunotherapy and other targeted therapy drugs for liver cancer, renal cell carcinoma, colorectal cancer and other solid tumors. We expect to file the IND application for ICP-033 in the first half of 2021; ICP-248: We intend to develop ICP-248 in combination with Orelabrutinib for the treatment of AML, ALL, FL, CLL, DLBCL and other hematological malignancies. We expect to file the IND application for ICP-248 in the first half of 2022; ICP-B03 – a tumor-conditional pro-interleukin (IL) – 15 targeting…We plan to apply for the IND application for ICP-B03 in the second half of 2022.”

IND • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor